EUVIMEDEUVIMED entdecken
Kohortenstudie

Juvenile‐Onset Recurrent Respiratory Papillomatosis and Human Papillomavirus Vaccine Uptake: A 19‐Year Retrospective Cohort Study

Alexandra F Corbin iD, Nick Sahlollbey iD, Gaayathri Varavenkataraman iD, Murilo de Santana Hager iD, Beatrice R Bacon iD, Michele M Carr iD

Otolaryngology–Head and Neck Surgery · 2026

DOI: 10.1002/ohn.70141 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2026. Verfasst von Alexandra F Corbin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Respiratory Tract Infections, Papillomavirus Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate 19‐year trends in juvenile‐onset recurrent respiratory papillomatosis incidence and treatment utilization in the context of increasing human papillomavirus vaccine uptake. Study Design Retrospective cohort study.

Setting

TriNetX United States Collaborative Network.

Methods

Children 18 years of age or younger with juvenile‐onset recurrent respiratory papillomatosis diagnosed between January 1, 2006, and December 31, 2024, were identified using International Classification of Diseases codes. Annual encounter‐based incidence per 100,000 patients was calculated for both juvenile‐onset recurrent respiratory papillomatosis and human papillomavirus vaccination. Within the pediatric juvenile‐onset recurrent respiratory papillomatosis cohort, annual utilization of major treatment modalities, including bevacizumab, cidofovir, lesion excision, and tracheostomy, was assessed.

Results

A total of 1854 children met inclusion criteria (mean age 7.9 ± 5.7 years). Juvenile‐onset recurrent respiratory papillomatosis incidence declined by 65.2%, from 3.1 cases per 100,000 in 2006 to 1.1 cases per 100,000 in 2024 ( P < .001). Human papillomavirus vaccine incidence increased by 1448.1%, from 45.5 to 704.4 cases per 100,000 patients over the same period ( P < .001). Annual juvenile‐onset recurrent respiratory papillomatosis incidence was inversely correlated with human papillomavirus vaccine incidence ( r = −0.892; P < .001). Within the pediatric juvenile‐onset recurrent respiratory papillomatosis cohort, use of bevacizumab and cidofovir increased significantly, whereas lesion excision and tracheostomy incidence remained stable.

Conclusion

Rising human papillomavirus vaccine uptake is associated with a significant reduction in encounter‐based juvenile‐onset recurrent respiratory papillomatosis incidence at the population level. Surgical excision remains the predominant management approach, with limited adoption of adjuvant therapies despite recent increases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsRespiratory Tract InfectionsPapillomavirus VaccinesHumansRetrospective StudiesFemaleMaleChildIncidenceChild, PreschoolCidofovirAntiviral AgentsUnited StatesAdolescentHuman Papillomavirus VirusesBevacizumab

Stichwörter der Autor:innen

bevacizumabcidofovirhuman papillomavirusrecurrent respiratory papillomatosisvaccine

Substanzen

Papillomavirus VaccinesCidofovirAntiviral AgentsBevacizumab

Autor:innen und Institutionen

  • Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Buffalo, New York, USA.
  • Department of Otolaryngology, Head and Neck Surgery, University of Calgary, Calgary, Alberta, Canada.
  • Department of Otolaryngology, Head and Neck Surgery, Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Buffalo, New York, USA.

ORCID-Profile: Alexandra F Corbin, Nick Sahlollbey, Gaayathri Varavenkataraman, Murilo de Santana Hager, Beatrice R Bacon, Michele M Carr

Zitieren

APA

Corbin, A. F., Sahlollbey, N., Varavenkataraman, G., de Santana Hager, M., Bacon, B. R., & Carr, M. M. (2026). Juvenile‐Onset Recurrent Respiratory Papillomatosis and Human Papillomavirus Vaccine Uptake: A 19‐Year Retrospective Cohort Study. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70141

Vancouver

Corbin AF, Sahlollbey N, Varavenkataraman G, de Santana Hager M, Bacon BR, Carr MM. Juvenile‐Onset Recurrent Respiratory Papillomatosis and Human Papillomavirus Vaccine Uptake: A 19‐Year Retrospective Cohort Study. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70141

BibTeX
@article{Corbin2026,
  author = {Corbin, Alexandra F and Sahlollbey, Nick and Varavenkataraman, Gaayathri and de Santana Hager, Murilo and Bacon, Beatrice R and Carr, Michele M},
  title = {Juvenile‐Onset Recurrent Respiratory Papillomatosis and Human Papillomavirus Vaccine Uptake: A 19‐Year Retrospective Cohort Study},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70141}
}
Kostenlos starten →